Neha Krishnamohan insider trades: Arcutis Biotherapeutics (ARQT) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Neha reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 13, 2025 | ARQT | ↓ Sell | 40,504 | $23.20 | $939K | Direct | Nov 17, 2025 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ARQT insiders
Open-market trades in the last 12 months
About Neha Krishnamohan's insider trades
Neha Krishnamohan is a director at Arcutis Biotherapeutics (ARQT). Since Nov 13, 2025, Neha has reported no open-market purchases and 1 sale worth $939K on SEC Form 4. In the last 12 months: 1 sale ($939K).
Their filings also include grants and awards (11 filings), shares withheld for taxes (8 filings), option exercises (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARQT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.